EVEREST MEDICINES
云 顶 新 耀

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

CHANGE OF NON-EXECUTIVE DIRECTOR

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of Everest Medicines Limited (the "**Company**") announces that Mr. William Ki Chul Cho ("**Mr. Cho**") has resigned as a non-executive director of the Company with effect from 14 August 2026 to devote more time to his other business endeavours.

Mr. Cho has confirmed that he has no disagreement with the Board and that there are no matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") relating to his resignation.

The Board wishes to express its sincere gratitude to Mr. Cho for his invaluable contributions to the Company during his tenure of service.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Yue Wang ("**Ms. Wang**") has been appointed as a non-executive Director with effect from 14 August 2026.

The biographical details of Ms. Wang are set out below:

Ms. Wang, aged 50, is currently the Operating Partner at CBC Group, a substantial shareholder of the Company. She has over 25 years of experience in pharmaceutical industry with over 15 years of experience in capital markets and investor relations. Prior to joining CBC Group, Ms. Wang was most recently a vice president of investor relations and public relations at Duality Biotherapeutics (a company listed on the Stock Exchange with stock code 09606.HK) from September 2024 to June 2025 and was a consultant at Duality Biotherapeutics during July 2025 to March 2026. Prior to that, Ms. Wang was a vice president of investor relations at Wuxi Biologics (Cayman) Inc. (a company listed on the Stock Exchange with stock code 02269.HK) during May 2017 to August 2024. Prior to that, Ms. Wang held positions in multiple pharmaceutical companies including Yichang HEC

ChangJiang Pharmaceutical Co., Ltd., China Traditional Chinese Medicine Co., Limited (a company listed on the Stock Exchange with stock code 00570.HK) and The United Laboratories International Holdings Limited (a company listed on the Stock Exchange with stock code 03933.HK). She has extensive senior-level experience spanning the entire healthcare industry value chain. She is an expert in global capital markets, corporate governance, corporate strategy, and corporate communications. Having navigated multiple capital market cycles, Ms. Wang is experienced in crisis management and has repeatedly led companies in capital market financing.

Ms. Wang received her MBA from Seton Hall University, her master's degree in Pharmaceutical Engineering from Jilin University and bachelor's degree in Pharmacy from Shenyang Pharmaceutical University.

Ms. Wang has entered into an appointment letter with the Company for a term of three years from 14 August 2026, subject to (i) retirement from office and re-election at the first annual general meeting of the Company after her appointment and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange (the "**Listing Rules**"). According to the terms of Ms. Wang's appointment, Ms. Wang will not receive any remuneration or benefits in her capacity as a non-executive Director but is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in the performance of her duties in connection with the business of the Company.

Save as disclosed above, as at the date of this announcement, Ms. Wang has confirmed that she does not hold (i) any other position with the Company or other members of the Group; (ii) any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; or (iii) any other major appointments and professional qualifications.

Save as disclosed above, as at the date of this announcement, Ms. Wang has also confirmed that she does not have (i) any relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; or (ii) any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there is no other information to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange relating to Ms. Wang's appointment.

The Board wishes to express its warmest welcome to Ms. Wang on her appointment.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 14 August 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.